First Tracks Biotherapeutics is trading 5.4% lower at $38.80 amid broader market weakness.

  • On September 23, 2026, the Nasdaq Composite was down 1.05%; rising crude oil and Treasury yields weighed on equity valuations.
  • No fresh company-specific announcement was identified; recent coverage points to previously disclosed clinical progress and investor conferences.
  • The move follows September 22’s 5.23% gain, suggesting a reversal of prior-session strength rather than a confirmed fundamental catalyst.